Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Table 3 Healthcare cost outcomes for the overall PSP cohort (N = 275)

	Mean annual HCRU cost per patient ($CAD)
Real-world cost outcome	Pre-mepolizumab	Post-mepolizumab	% change
GP visit (asthma-related)	$83.55	$52.54	–37.1***
Specialist visit (asthma-related)	$390.74	$246.82	–36.8***
ED visits (all-cause)	$602.69	$447.82	–25.7**
Hospital admission (all-cause)^†	$4,372.92	$2,885.32	–34.0
HCRU (excluding drug cost)^‡	$6,214.42	$4,109.12	–33.9*

*P < 0.05
**P < 0.01
***P < 0.001
^†Due to resource intensity weighting, costs cannot be accurately estimated from specific hospital admission reasons; thus, costs are not asthma-specific
^‡HCRU includes all factors listed in table as well as other asthma-related physician costs for shadow billings, where the location was other than home, office, or phone
$CAD, Canadian dollars; ED, emergency department; GP, general practitioner; HCRU, healthcare resource utilization; PSP, patient support program

ISSN: 1710-1492